Targeting Ret Alterations With Selective Inhibitor Blu-667

Targeting RET Alterations With Selective Inhibitor BLU-667

Targeted Oncology

Treating RET alterations with novel therapy BLU-667

First-in-human trial results of RET targeted BLU-667

Dr. Subbiah on Safety and Efficacy of BLU-667 in RET-Altered Solid Tumors

Frequency of RET Alterations in Thyroid Cancers

Targeted Oncology

A Visual Exploration of New Opportunities in Thyroid Cancer: Targeting RET Alterations

PeerView Oncology

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers

Otolaryngologist,ORL,ENT-Medical Office,Artz Praxis

Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET f...

RET inhibition in RET aberrant cancers

ARROW: clinical activity of pralsetinib in RET-fusion positive solid tumors

Selpercatinib for RET-Altered Thyroid Cancers

Selpercatinib in RET-altered Thyroid Cancers with Dr. Lori Wirth

THANC Foundation

Pralsetinib for Advanced or Metastatic RET-Altered Thyroid Cancer with Dr. Vivek Subbiah

THANC Foundation

LIBRETTO-001: Targeting RET Fusions in Advanced-Stage NSCLC

RET As a Target in Lung Cancer

The Society for Translational Oncology

Dr. Drilon on Efficacy Results With LOXO-292 in RET-Altered Solid Tumors

Dr. Gainor on Potential With BLU-667 in RET+ NSCLC

BOS172738 in RET-altered tumors

Fine-Tuning Biomarker Testing to Identify and Target RET Fusions in NSCLC

PeerView Oncology

ARROW study: pralsetinib in RET fusion+ tumors